Skip to content
Search

Latest Stories

1 in 3 ethnic minorities need 3 or more GP visits for cancer diagnosis, new survey reveals

1 in 3 ethnic minorities need 3 or more GP visits for cancer diagnosis, new survey reveals
Currently, only 60 per cent of cancer diagnoses are taking place before the cancer has progressed

The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system.

Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication, particularly for individuals from Mixed, Black, or Asian backgrounds.


Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals before receiving a cancer diagnosis.

Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across the population.

These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience.

Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.

A substantial proportion of patients from deprived areas reported feeling inadequately informed about the reasons for their referrals and faced challenges in fully understanding their diagnosis.

Moreover, the analysis suggested that people from the most deprived populations in England were 21 per cent less likely to be referred for urgent suspected cancer than those from areas with low levels of deprivation.

This highlights systemic barriers in effective patient-provider communication, which are critical for informed decision-making and navigating the complexities of cancer care.

Dr. Liz Fisher, Senior Fellow at the Nuffield Trust, emphasized the urgency of addressing these disparities, noting that early diagnosis is pivotal for improving cancer survival rates.

"Detecting cancer early is vital to improving survival rates, for example, the rate of survival for bowel cancer drops significantly from 80 per cent if caught in stage 2 to 11 per cent at stage four."

She emphasised the need to enhance primary care capacity and provide tailored support for ethnic minority communities as essential to ensure equitable access to timely diagnosis and support services.

Tim Gardner, Assistant Director of Policy at the Health Foundation, echoed these sentiments, stressing the need for sustained investment in primary care to address underlying structural inequities in cancer care delivery.

He further suggested that by prioritizing culturally sensitive approaches and addressing communication barriers, healthcare providers can work towards narrowing the gap in cancer outcomes among most deprived populations.

The Nuffield Trust report also predicted higher chances of NHS missing its own target to have 75 per cent of cancers diagnosed at an early stage by 2028 as efforts to diagnose cancer at earlier stages has flatlined in recent years and currently, only 60 per cent of cancer diagnoses are taking place before the cancer has progressed.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less